Improving vaccination rates in high-risk groups

Video

A look at a recently presented study on improving 23-valent pneumococcal polysaccharide vaccine uptake in groups that are at high risk.

Anthony W. Gannon, MD, a pediatric endocrinilogist at Nemours Children's in Wilmington, Delaware, sat down with Contemporary Pediatrics to discuss a poster presented at the 2022 Pediatric Academic Societies meeting that examined the impact of a quality improvement program on improving 23-valent pneumococcal polysaccharide vaccine uptake in 3 groups that are at high risk. He shared the ins and outs of the research, how other health systems could consider a similar project, and what the next steps are.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.